Drug intelligence / Profile preview

CT0591CP

Development stage: Phase 1
Lead developer: First Affiliated Hospital of Soochow University
Modality: Cell Therapies
Administration: Intravenous

Overview

CT0591CP is an investigational cell therapy being evaluated for the treatment of relapsed and/or refractory multiple myeloma. It is currently in early phase 1 clinical trials, with studies focused on assessing its safety and tolerability in patients who have not responded to or have relapsed after standard therapies. The therapy is developed by The First Affiliated Hospital of Soochow University. While the precise mechanism of action and cellular engineering details (such as target antigen or cell type) are not specified in public sources, it falls under the category of advanced cellular immunotherapy for hematologic malignancies[2][6].

Other names: CT0591CP cellCT-0591CP cellCT 0591CP cell

Beyond the preview

Go deeper on CT0591CP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT0591CP.

Explore the full profile